ioGlutamatergic Neurons Huntington's Disease HTT 50CAG/WT Human iPSC-derived glutamatergic neurons

The abnormal expansion of 50 CAG repeats was introduced in the first exon of the Huntingtin gene using CRISPR/Cas9 genome editing. ioGlutamatergic Neurons are available as the genetically matched control for the ioGlutamatergic Neurons HTT^50CAG/WT disease model. This disease model and isogenic control offer a fast and easy-to-use system for investigating the impact of gene function on Huntington’s disease progression in research and drug discovery settings.

ioGlutamatergic Neurons HTT^50CAG/WT express pan-neuronal and glutamatergic markers TUBB3, MAP2, and VGLUT2 by day 11, as well as the disease-relevant Huntingtin protein. bit.bio’s opti-ox™ cellular reprogramming enables the consistent manufacture of homogenous and mature hiPSCs derived functional neurons within days, offering access to the highest quality cellular CNS model with simple protocols.

ioGlutamatergic Neurons cells provide you with:

• Consistency: Batch-to-batch reproducibility and homogeneity create a stable human model for excitatory neuronal activity and disease
• Speed: Ready for experimentation as early as two days post revival and form functional neuronal networks at 17 days
• Scalability: Industrial-scale quantities allow the cells to be used in a range of applications, from research to screening purposes
• Ease of Use: Cells arrive programmed to rapidly mature upon revival with only one medium required in a two-step protocol